Perspective Therapeutics announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01, its targeted alpha-particle therapy, in development for the treatment of MC1R-positive metastatic melanoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CATX:
- Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma
- Perspective Therapeutics’ VMT-a-NET protocols presented at NANETS sympsium
- Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference
- Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
- Perspective Therapeutics to present at World Molecular Imaging Congress